Overview

Pharmacokinetics and Safety of BI 695501

Status:
Completed

Trial end date:
2017-02-23

Target enrollment:

Participant gender:

Summary

To characterize and compare the pharmacokinetics and to assess the safety of BI 695501 after single injection using either auto injector or prefilled syringe.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim